Christopher Geven Targeting Adrenomedullin in sepsis
Sepsis is a severe and common problem in patients admitted to Intensive Care units. There remains a large and unmet need for new therapies. Christopher Geven investigated the role of the hormone adrenomedullin in sepsis and a new drug that targets this hormone (Adrecizumab).read more
Christopher Geven Targeting Adrenomedullin in sepsisSepsis is a severe and common problem in patients admitted to Intensive Care units. There remains a large and unmet need for new therapies. Christopher Geven investigated the role of the hormone adrenomedullin in sepsis and a new drug that targets this hormone (Adrecizumab). First, the relation between the adrenomedullin concentration in the blood and the prognosis of patients was investigated. This concentration had a strong predictive value for patient outcome. Next, the efficacy of Adrecizumab was investigated in animal models of sepsis. Adrecizumab had several beneficial effects: it reduced vascular leakage and edema formation while improving blood pressure and survival. Thereafter, the safety and pharmacokinetics of Adrecizumab were investigated for the first time in healthy human volunteers, which revealed a favourable safety profile. Finally, the design of the first clinical trial in patients with septic shock is described, which has several unique characteristics.
Date, time and location PhD defense
- Date: 15 March 2019
- Time: 10:30 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
Christopher Geven (1990) studied Medicine at the Radboud University and obtained his medical degree in 2014. In the year hereafter he worked as a medical doctor at the department of Intensive Care medicine at the Radboud university medical center. He carried out the above doctoral research within this department, and within the Radboud Institute for Molecular Life Sciences.
- Promotor(s): Prof. P. Pickkers
- Co-promotor(s): M. Kox, PhD